APO RESEARCH · REPORT
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug
Selected research
Market Outlook & Growth Opportunities
Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Outlook and Growth Opportunities 2026
Market perspective
The global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market include Novartis AG, Pfizer Inc, AstraZeneca Plc, Seattle Genetics Inc, NuvOx Pharma LLC, Modus Therapeutics Holding AB, Gilead Sciences Inc and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market.
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Company
Novartis AG
Pfizer Inc
AstraZeneca Plc
Seattle Genetics Inc
NuvOx Pharma LLC
Modus Therapeutics Holding AB
Gilead Sciences Inc
Bristol-Myers Squibb Company
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Type
SGD-2083
Crizanlizumab
PF-04447943
NVX-508
Others
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Application
Clinic
Hospital
Others
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug key companies, revenue, market share, and recent developments.
3. To split the Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug industry.
Chapter 3: Detailed analysis of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Trends
Table 2. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Drivers
Table 3. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Opportunities and Challenges
Table 4. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Restraints
Table 5. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Company (2021-2026)
Table 7. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Key Company Manufacturing Base & Headquarters
Table 9. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Company, Product Type & Application
Table 10. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of SGD-2083
Table 15. Significant Companies of Crizanlizumab
Table 16. Significant Companies of PF-04447943
Table 17. Significant Companies of NVX-508
Table 18. Significant Companies of Others
Table 19. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 20. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Type (2021-2026) & (US$ Million)
Table 21. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Type (2027-2032) & (US$ Million)
Table 22. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type (2021-2026)
Table 23. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type (2027-2032)
Table 24. Significant Companies of Clinic
Table 25. Significant Companies of Hospital
Table 26. Significant Companies of Others
Table 27. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 28. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Application (2021-2026) & (US$ Million)
Table 29. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Application (2027-2032) & (US$ Million)
Table 30. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application (2021-2026)
Table 31. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application (2027-2032)
Table 32. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 33. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Region (2021-2026) & (US$ Million)
Table 34. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Region (2021-2026)
Table 35. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Region (2027-2032) & (US$ Million)
Table 36. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Region (2027-2032)
Table 37. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 38. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Country (2021-2026) & (US$ Million)
Table 39. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Market Share by Country (2021-2026)
Table 40. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Country (2027-2032) & (US$ Million)
Table 41. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Market Share by Country (2027-2032)
Table 42. Novartis AG Company Information
Table 43. Novartis AG Business Overview
Table 44. Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 45. Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
Table 46. Novartis AG Recent Development
Table 47. Pfizer Inc Company Information
Table 48. Pfizer Inc Business Overview
Table 49. Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 50. Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
Table 51. Pfizer Inc Recent Development
Table 52. AstraZeneca Plc Company Information
Table 53. AstraZeneca Plc Business Overview
Table 54. AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 55. AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
Table 56. AstraZeneca Plc Recent Development
Table 57. Seattle Genetics Inc Company Information
Table 58. Seattle Genetics Inc Business Overview
Table 59. Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 60. Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
Table 61. Seattle Genetics Inc Recent Development
Table 62. NuvOx Pharma LLC Company Information
Table 63. NuvOx Pharma LLC Business Overview
Table 64. NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 65. NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
Table 66. NuvOx Pharma LLC Recent Development
Table 67. Modus Therapeutics Holding AB Company Information
Table 68. Modus Therapeutics Holding AB Business Overview
Table 69. Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 70. Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
Table 71. Modus Therapeutics Holding AB Recent Development
Table 72. Gilead Sciences Inc Company Information
Table 73. Gilead Sciences Inc Business Overview
Table 74. Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 75. Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
Table 76. Gilead Sciences Inc Recent Development
Table 77. Bristol-Myers Squibb Company Company Information
Table 78. Bristol-Myers Squibb Company Business Overview
Table 79. Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
Table 81. Bristol-Myers Squibb Company Recent Development
Table 82. Research Programs/Design for This Report
Table 83. Authors List of This Report
Table 84. Secondary Sources
Table 85. Primary Sources
List of Figures
Figure 1. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Image
Figure 2. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million)
Figure 4. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. SGD-2083 Image
Figure 8. Crizanlizumab Image
Figure 9. PF-04447943 Image
Figure 10. NVX-508 Image
Figure 11. Others Image
Figure 12. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 13. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 14. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type (2021-2032)
Figure 15. Clinic Image
Figure 16. Hospital Image
Figure 17. Others Image
Figure 18. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 19. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 20. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application (2021-2032)
Figure 21. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 22. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 23. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 24. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 25. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 26. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 27. Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 28. Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 29. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 30. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 31. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 32. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 33. USA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 34. USA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 35. USA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 36. Canada Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 37. Canada Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 38. Canada Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 39. Mexico Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 40. Mexico Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 41. Mexico Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 42. Germany Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 43. Germany Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 44. Germany Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 45. France Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 46. France Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 47. France Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 48. U.K. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 49. U.K. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 50. U.K. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 51. Italy Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 52. Italy Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 53. Italy Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 54. Spain Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 55. Spain Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 56. Spain Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 57. Russia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 58. Russia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 59. Russia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 60. Netherlands Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 61. Netherlands Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 62. Netherlands Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 63. Nordic Countries Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 64. Nordic Countries Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 65. Nordic Countries Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 66. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 67. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 68. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 69. Japan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 70. Japan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 71. Japan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 72. South Korea Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 73. South Korea Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 74. South Korea Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 75. India Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 76. India Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 77. India Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 78. Australia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 79. Australia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 80. Australia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 81. Southeast Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 82. Southeast Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 83. Southeast Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 84. Brazil Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 85. Brazil Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 86. Brazil Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 87. Argentina Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 88. Argentina Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 89. Argentina Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 90. Chile Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 91. Chile Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 92. Chile Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 93. Colombia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 94. Colombia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 95. Colombia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 96. Peru Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 97. Peru Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 98. Peru Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 99. Saudi Arabia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 100. Saudi Arabia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 101. Saudi Arabia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 102. Israel Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 103. Israel Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 104. Israel Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 105. UAE Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 106. UAE Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 107. UAE Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 108. Turkey Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 109. Turkey Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 110. Turkey Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 111. Iran Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 112. Iran Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 113. Iran Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 114. Egypt Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 115. Egypt Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 116. Egypt Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 117. Years Considered
Figure 118. Research Process
Figure 119. Key Executives Interviewed
Scope & coverage.
Types
- SGD-2083
- Crizanlizumab
- PF-04447943
- NVX-508
- Others
Applications
- Clinic
- Hospital
- Others
Companies covered
- Novartis AG
- Pfizer Inc
- AstraZeneca Plc
- Seattle Genetics Inc
- NuvOx Pharma LLC
- Modus Therapeutics Holding AB
- Gilead Sciences Inc
- Bristol-Myers Squibb Company
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Dynamics
- 2.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Trends
- 2.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Drivers
- 2.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Opportunities and Challenges
- 2.4 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Restraints
3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market by Company
- 3.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Company Revenue Ranking in 2025
- 3.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Company (2021-2026)
- 3.3 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Company Ranking (2024-2026)
- 3.4 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Company Manufacturing Base and Headquarters
- 3.5 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Company Product Type and Application
- 3.6 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market by Type
- 4.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Type Introduction
- 4.1.1 SGD-2083
- 4.1.2 Crizanlizumab
- 4.1.3 PF-04447943
- 4.1.4 NVX-508
- 4.1.5 Others
- 4.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Type
- 4.2.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Type (2021-2032)
- 4.2.3 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type (2021-2032)
5 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market by Application
- 5.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Application Introduction
- 5.1.1 Clinic
- 5.1.2 Hospital
- 5.1.3 Others
- 5.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Application
- 5.2.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Application (2021-2032)
- 5.2.3 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application (2021-2032)
6 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Regional Value Analysis
- 6.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Region (2021-2032)
- 6.2.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Region: 2021-2026
- 6.2.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value (2021-2032)
- 6.3.2 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value (2021-2032)
- 6.4.2 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value (2021-2032)
- 6.6.2 South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Country, 2025 VS 2032
7 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Country-level Value Analysis
- 7.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Country (2021-2032)
- 7.2.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Country (2021-2026)
- 7.2.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.7.2 France Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.14.2 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.17.2 India Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Novartis AG
- 8.1.1 Novartis AG Company Information
- 8.1.2 Novartis AG Business Overview
- 8.1.3 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
- 8.1.4 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 8.1.5 Novartis AG Recent Developments
- 8.2 Pfizer Inc
- 8.2.1 Pfizer Inc Company Information
- 8.2.2 Pfizer Inc Business Overview
- 8.2.3 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
- 8.2.4 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 8.2.5 Pfizer Inc Recent Developments
- 8.3 AstraZeneca Plc
- 8.3.1 AstraZeneca Plc Company Information
- 8.3.2 AstraZeneca Plc Business Overview
- 8.3.3 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
- 8.3.4 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 8.3.5 AstraZeneca Plc Recent Developments
- 8.4 Seattle Genetics Inc
- 8.4.1 Seattle Genetics Inc Company Information
- 8.4.2 Seattle Genetics Inc Business Overview
- 8.4.3 Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
- 8.4.4 Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 8.4.5 Seattle Genetics Inc Recent Developments
- 8.5 NuvOx Pharma LLC
- 8.5.1 NuvOx Pharma LLC Company Information
- 8.5.2 NuvOx Pharma LLC Business Overview
- 8.5.3 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
- 8.5.4 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 8.5.5 NuvOx Pharma LLC Recent Developments
- 8.6 Modus Therapeutics Holding AB
- 8.6.1 Modus Therapeutics Holding AB Company Information
- 8.6.2 Modus Therapeutics Holding AB Business Overview
- 8.6.3 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
- 8.6.4 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 8.6.5 Modus Therapeutics Holding AB Recent Developments
- 8.7 Gilead Sciences Inc
- 8.7.1 Gilead Sciences Inc Company Information
- 8.7.2 Gilead Sciences Inc Business Overview
- 8.7.3 Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
- 8.7.4 Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 8.7.5 Gilead Sciences Inc Recent Developments
- 8.8 Bristol-Myers Squibb Company
- 8.8.1 Bristol-Myers Squibb Company Company Information
- 8.8.2 Bristol-Myers Squibb Company Business Overview
- 8.8.3 Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
- 8.8.4 Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 8.8.5 Bristol-Myers Squibb Company Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst